Read More

Syndax Presents Data From Pivotal AUGMENT-101 Trial Of Revumenib In Relapsed/Refractory KMT2Ar Acute Leukemia At Oral Presentation During ASH Meeting; Trial Met Its Primary Endpoint At Interim Analysis Of The Pooled KMT2Ar AML And ALL Cohorts

– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate consistent across adult and pediatric patients –– 63% overall response

SNDX

Read More

Reported December 11, “Watchdog Calls On U.S. To Ban Candy Cancer Chemicals As UK Begins Seizing Mountain Dew, Jolly Rancher, Swedish Fish And Lemonhead Amid Crackdown On American Junk Food That Is Linked To Infertility And Health Issues” – Daily Mail

https://www.dailymail.co.uk/health/article-12850721/us-candy-cancer-chemicals-seized-uk.html#:~:text=The%20watchdog%20Consumer%20Reports%20said,outlawed%20in%20Europe%20years%20ago.A US watchdog has told DailyMail.com

HSY

Read More

TransCode Therapeutics Reports Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138; Study Demonstrated TTX-MC138 Effective Against Metastatic Pancreatic Cancer On Animal Models

The study involved weekly injection of TTX-MC138 into animals bearing human pancreatic tumors. Treatment was initiated after the tumors were established and continued for 8 weeks. Untreated animals and animals treated

RNAZ